Ionis completes enrollment in Phase 3 Angelman syndrome study

July 6, 2026 7:00 AM

Ionis Pharmaceuticals (Nasdaq: IONS) has completed enrollment in the pivotal cohort of its global Phase 3 REVEAL study evaluating obudanersen ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found